This competitive renewal application of P01 CA100730 seeks funds to continue the study of highly integrated retrovirus models to elucidate essential cellular mechanisms that define lymphocyte transformation and disease. The study of retroviruses has provided fundamental and critical knowledge for defining the mechanisms of cell transformation as well as fundamental paradigms of cell biology. The interactive nature, established record of collaborations, and focus of the individual projects and cores that constitute the proposed PPG continuation are directly supportive of NCI's strategic plans and goals. Our goals were realized with robust productivity over the last four years demonstrated by 64 peer-reviewed manuscripts 70% interactive between PPG investigators. The continuation of the Program will extend upon the established interactions through inter-related goals to define critical events that control the transition of lymphocytes from activation through immortalization and transformation. Project 1 uses retroviruses to provide novel insights into how they alter transcription and DNA damage/repair signaling to establish persistent infections and set the stage for cellular transformation. Project 2 (Dr. Green) will define novel post-transcriptional mechanisms of retroviruses and working together with Dr. Lairmore (Project 1), will comparatively test each protein in viral replication and lymphocyte transformation. Project 3 working collaboratively with multiple PPG investigators will examine the fundamental translational control mechanisms in both retroviruses and in crucial growth control genes. Project 4 (Drs. Weilbaecher, Washington University and Rosol, Ohio State University) combine their expertise with PPG investigators to study the role of bone microenvironment in osteolytic and osteoblastic tumor models. Project 5 (Dr. Ratner) continues the highly dynamic collaborations between each University to test the contribution of the inflammatory microenvironment in carcinogenesis using unique transgenic mouse models. The PPG consists of five interactive Projects and three highly supportive Cores. Each project is related to two central components involving the regulation of lymphocyte signaling and gene expression by retroviruses or alterations of the cellular microenvironment leading to transformation and paraneoplastic disease. The interactive nature of the PPG will provide rationale hypotheses to support translational studies to define therapeutic intervention against retrovirus-induced lymphoma and refine animal models to determine molecular determinants of retrovirus-induced cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S (O1))
Program Officer
Read-Connole, Elizabeth Lee
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Veterinary Sciences
Schools of Veterinary Medicine
United States
Zip Code
Panfil, Amanda R; Dissinger, Nathan J; Howard, Cory M et al. (2016) Functional Comparison of HBZ and the Related APH-2 Protein Provides Insight into Human T-Cell Leukemia Virus Type 1 Pathogenesis. J Virol 90:3760-72
Esser, Alison K; Schmieder, Anne H; Ross, Michael H et al. (2016) Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model. Nanomedicine 12:201-11
Su, Xinming; Esser, Alison K; Amend, Sarah R et al. (2016) Antagonizing Integrin β3 Increases Immunosuppression in Cancer. Cancer Res 76:3484-95
Kawatsuki, A; Yasunaga, J-I; Mitobe, Y et al. (2016) HTLV-1 bZIP factor protein targets the Rb/E2F-1 pathway to promote proliferation and apoptosis of primary CD4(+) T cells. Oncogene 35:4509-17
Murphy, Jane; Hall, William W; Ratner, Lee et al. (2016) Novel interactions between the HTLV antisense proteins HBZ and APH-2 and the NFAR protein family: Implications for the HTLV lifecycles. Virology 494:129-42
Niewiesk, Stefan (2016) Animals Models of Human T Cell Leukemia Virus Type I Leukemogenesis. ILAR J 57:3-11
Panfil, Amanda R; Martinez, Michael P; Ratner, Lee et al. (2016) Human T-cell leukemia virus-associated malignancy. Curr Opin Virol 20:40-46
Kroep, J R; Charehbili, A; Coleman, R E et al. (2016) Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials. Eur J Cancer 54:57-63
Haines, Robyn A; Urbiztondo, Rebeccah A; Haynes 2nd, Rashade A H et al. (2016) Characterization of New Zealand White Rabbit Gut-Associated Lymphoid Tissues and Use as Viral Oncology Animal Model. ILAR J 57:34-43
Ratner, L; Rauch, D; Abel, H et al. (2016) Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer J 6:e408

Showing the most recent 10 out of 146 publications